CCEL
Cryo-Cell International, Inc.
CCEL trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over CCEL overall, supported by stronger fundamentals and lower modeled downside.
CCEL Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Stable | |
| Weak |
CCEL's revenue and cash flow are currently stable, but its profitability and balance sheet are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CCEL PE Valuation
CCEL has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 68x next year's earnings.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CCEL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Decline | |
| -- | |
| Limited | |
| -- |
Analysts expect CCEL to return to profit, with revenue declining.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CCEL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.08 | — |
| Q3 2026 | -$0.22 | -$0.15 |
| Q2 2026 | -$0.29 | -$0.26 |
| Q1 2026 | -$0.32 | -3300% |
| Q4 2025 | -$0.30 | -700% |
| Q3 2025 | -$0.07 | +$0.99 |
| Q2 2025 | -$0.03 | +$1.08 |
| Q1 2025 | $0.01 | +$1.17 |
| Q4 2024 | $0.05 | +$1.19 |
CCEL is still losing money, but far less than before: $0.22 per share over the past year, against $1.16 at its worst in early 2024.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CCEL on earnings quality, reporting a profit while its opponent remains loss making.
CCEL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.8M | 0% |
| Q2 2026 | $7.8M | -1.9% |
| Q1 2026 | $7.7M | -3.6% |
| Q4 2025 | $7.8M | -2.3% |
| Q3 2025 | $7.8M | -3% |
| Q2 2025 | $7.9M | -1.4% |
| Q1 2025 | $8M | +1.5% |
| Q4 2024 | $8M | +1.9% |
CCEL's revenue has held roughly level: $8M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 28% | +3.8 points |
| Q2 2026 | 15% | -3.4 points |
| Q1 2026 | 10% | -3.3 points |
| Q4 2025 | -51% | -49 points |
| Q3 2025 | 24% | +7.1 points |
| Q2 2025 | 19% | +1.5 points |
| Q1 2025 | 13% | +2.8 points |
| Q4 2024 | -1.5% | +204 points |
CCEL's operating margin was 28% last quarter, up 3.8 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CCEL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CCEL on profitability, with a higher operating margin.
CCEL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1M | -58% |
| Q2 2026 | $1.8M | +181% |
| Q1 2026 | $584.8K | -34% |
| Q4 2025 | $1.2M | -44% |
| Q3 2025 | $2.5M | +11% |
| Q2 2025 | $644.6K | +2891% |
| Q1 2025 | $892K | +$1.7M |
| Q4 2024 | $2.1M | +32% |
CCEL still generates free cash flow, though less than at its 2020 peak: $5M over the past year.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CCEL on cash flow, with more consistent year-over-year improvement.
CCEL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +9.7K shares |
| 1 year | -0.1% | -8.5K shares |
| 3 years | -3.3% | -277K shares |
| 5 years | -7.2% | -627K shares |
| Available history | -4.1% | -347K shares |
CCEL has 8M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $80,883 |
| Q2 2025 | $88,619 |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | $16,400 |
| Q2 2024 | $1.2M |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CCEL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CCEL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.5x | High |
| Q2 2026 | 10.3x | High |
| Q1 2026 | 7.7x | High |
| Q4 2025 | 6.0x | High |
| Q3 2025 | 1.6x | Healthy |
| Q2 2025 | 1.8x | Healthy |
| Q1 2025 | 1.8x | Healthy |
| Q4 2024 | 2.0x | Healthy |
CCEL's net debt is about 6.5 years of its operating earnings (EBITDA), up from 1.6 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over CCEL on leverage, with a lower net debt burden relative to earnings.
CCEL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 66.8 | Neutral |
| Stochastic | 88.0 | Overbought |
CCEL's weekly RSI is 67 (neutral) and its Stochastic is 88 (overbought).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CCEL PE vs Healthcare Sector
| Metric | CCEL | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CCEL has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CCEL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.62 | 17% above |
| 20 week MA | $4.16 | 30% above |
| 50 week MA | $3.75 | 44% above |
| 100 week MA | $4.69 | 15% above |
| 200 week MA | $5.37 | 0.6% above |
CCEL has climbed back above all five of its weekly moving averages, and it's now 0.6% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
CCEL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.22 | $7.50 | +3.9% |
| 2021 | $7.50 | $12.4 | +65% |
| 2022 | $12.4 | $4.30 | -65% |
| 2023 | $4.30 | $5.75 | +34% |
| 2024 | $5.75 | $7.72 | +34% |
| 2025 | $7.72 | $3.50 | -55% |
| 2026 YTD | $3.50 | $5.40 | +54% |
CCEL has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.